Indoco Remedies Ltd (NSE:INDOCO)

Q1 2027 Indoco Remedies Ltd Earnings Call Transcript

Jul 28, 2026 / 10:00 AM GMT

Release Date Price: ₹228.05 (-8.10%)

Transcript

Key Points

Positve

Indoco Remedies Ltd (BOM:532612) reported a year-on-year standalone operational revenue growth of 5.8% to $4081 million, with consolidated revenue increasing by 8.2% to $4662 million.
The company achieved a standalone EBITDA margin of 10.3%, reflecting strong operational momentum.
Successful regulatory audits were completed, including EU GMP certification for Baddi Unit 3 and a zero-observation pre-approval inspection by the US FDA at the Indoco Stability Center.
The domestic formulations business recorded revenues of $2040 million, maintaining a solid position in the Indian pharma market.
International formulations contributed 35% of Q1 FY27 revenue, with the US business growing by 62.2% year-on-year.

Negative

The company faced a decline in gross margins due to increased costs of goods, impacted by supply chain issues and material shortages.
Emerging markets experienced a revenue decline, attributed to temporary market conditions and product availability challenges.
The European market showed flat growth, with timing issues affecting product releases.
Debt levels remain high, with a total debt of around 930 crore, impacting financial flexibility.
The US business, particularly the sterile segment, is not yet profitable due to ongoing regulatory challenges and remediation costs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INRM.NS - Indoco Remedies Ltd
Q1 2027 Indoco Remedies Ltd Earnings Call
Jul 28, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Indoco Remedy's Q1 FY27 earnings conference call. As a reminder, all participant lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing then 0 on your touchstone phone. Please note that this conference is being recorded.

I now hand the conference over to Ms. Rashmi Shetty from Daulat Capital Markets Limited.

Thank you and over to you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.